



## Drug Monograph

Drug/Drug **Daliresp<sup>®</sup> (roflumilast) tablet /COPD**

Class:

Prepared for: MO HealthNet

Prepared by: Conduent

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

<b>Purpose:</b>	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
<b>Dosage Forms:</b>	Daliresp <sup>®</sup> is now available in a tablet containing 250 mcg roflumilast.
<b>Manufacturer:</b>	AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850
<b>Indications:</b>	Daliresp <sup>®</sup> is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
<b>Costs:</b>	\$11.68 per tab of Daliresp <sup>®</sup> . Wholesale Acquisition Cost
<b>Summary of Findings:</b>	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).
<b>Status Recommendation:</b>	<input type="checkbox"/> Prior Authorization (PA) Required <input type="checkbox"/> Open Access <input type="checkbox"/> Fiscal Edit <input checked="" type="checkbox"/> PDL
<b>Type of PA Criteria:</b>	<input type="checkbox"/> Increased Risk of ADE <input checked="" type="checkbox"/> Non-Preferred <input type="checkbox"/> Appropriate Indications <input type="checkbox"/> No PA Required

Prepared By: Luke Boehmer PharmD  
Date: May 30, 2018